Ligand Pharmaceuticals Incorporated (LGND)

Invesco Ltd. has reported a 6.1% beneficial ownership stake in Ligand Pharmaceuticals Inc., according to a recent SCHEDULE 13G SEC filing. This represents 1,218,846 shares of Ligand's common stock, with Invesco exercising sole voting power over 1,199,033 shares and sole dispositive power over all 1,218,846 shares. The shares are held by Invesco's advisory clients, none of whom hold more than 5% economic ownership individually.

Ligand Pharmaceuticals reported strong Q2 2026 results, driven by increased royalty revenue and adjusted earnings, and highlighted the strategic acquisition of XOMA Royalty. The company raised its full-year adjusted EPS guidance and outlined significant deployable capital for future business development. Ligand also detailed its expanded commercial portfolio and pipeline catalysts, including several key programs and upcoming trial readouts.

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Ligand Pharmaceuticals Incorporated (LGDN). It provides a detailed table including each ETF's market value, weight of LGDN in the fund, issuer, management style, focus (e.g., small cap, health care), expense ratio, assets under management (AUM), current price, change percentage, relative volume, and 3-year NAV total return. The information helps investors identify funds with exposure to Ligand Pharmaceuticals and assess their characteristics.

Ligand Pharmaceuticals has successfully completed a $700 million private offering of 0.00% Convertible Senior Notes due 2031 to enhance its liquidity and financial flexibility. To mitigate dilution, the company entered into convertible note hedge transactions covering approximately 2.09 million shares and sold warrants with a $524.34 strike price, covering about 4.19 million shares, to help offset hedging costs. The notes are initially convertible at $334.27 per share and are senior unsecured.

Ligand Pharmaceuticals announced a private offering of $550 million in convertible senior notes due 2031, with an option for an additional $82.5 million. The company plans to use part of the proceeds for convertible note hedge and warrant transactions, repurchase up to $75 million of its common stock, and fund general corporate purposes, including the acquisition of Xoma Royalty Corporation. Concurrently, a Fourth Amendment to its Credit Agreement was made, adjusting minimum Consolidated EBITDA requirements to facilitate this offering.